

FlexGen



Content

- The Company
- FlexArrayer
- FlexGen's markets
- Public-Private Partnerships
- Examples
- Challenges & Conclusions

FlexGen – the Company

History

Collaboration of Dutch Space and Leiden University & Medical Centre

Application of “space technologies” in unmet needs in the life sciences

Company founded in 2004

Private & Public investors

Location

Leiden, Bioscience Park, the Netherlands

Product

FlexArrayer; instrument for fast flexible array synthesis




Technology

FlexArrayer:

instrument for creating custom microarrays

- DNA probes in situ synthesized
- Photo-deprotection
- Single wavelength laser positioned with two mirrors
- Standard glass slide format



Concept; Freedom to Innovate

FAST

New arrays in one day



FLEXIBLE

- Permits synthesis of all custom sequences
- Freedom to design array lay-out
- Compatible with standard microarray equipment
- Freedom to adjust synthesis chemistry


FOCUSED

- Rapid analysis of targets of interest
- Suitable for subarrays
- Ensures confidentiality

Markets



The Challenge in Life Science



FlexArrayer – Markets

Genomic Selection

Targeted capture of regions of interest prior to NGS

Biomarker Validation

Validation of candidate biomarkers

Technology Innovators

Development of new microarray applications

Synthetic biology



FlexGen & P-P Partnerships



FlexGen & P-P Partnerships

- FlexGen encompasses range of exciting applications
 - Pharmacogenomics
 - Synthetic Biology
- FlexArrayer provides fast & flexible research tool; of interest to top research institutes
- P-P Partnerships Provide;
 - Access to excellent scientists
 - Opportunity to generate new IP
 - High profile publications
 - Customer feedback; partners also work with competing technologies

FlexGen & P-P Partnerships

- Range of confidential high-profile research groups in the Netherlands, the UK, US
- Focus; genomic selection & synthetic biology

P-P Partnerships; CTMM

- Center for Translational Molecular Medicine
- Circulating Cells
 - Biomarker development for atherosclerosis
 - A.o.; AMZ, EMC, Philips, InterRNA, Beckman Coulter
- BioChip
 - Biomarker development for Leukemia
 - A.o.; Erasmus Medical Centre, University of Edinburgh
- TRACER
 - Biomarker development for rheumatoid arthritis
 - A.o.; VUMC, AMC, LUMC, EMC, Roche, Schering Plough
- MARS
 - Risk stratification of Sepsis
 - A.o.; AMC, Radboud, UMCU, Philips

Challenges in P-P Partnerships

Public vs. Private

Challenges in P-P Partnerships

Public vs. Private

Urge to publish vs. Generate IP

Challenges in P-P Partnerships

Public vs. Private

Urge to publish vs. Generate IP

Highly specific interest vs. Broadly applicable product

Challenges in P-P Partnerships

Public vs. Private

Urge to publish vs. Generate IP

Highly specific interest vs. Broadly applicable product

Publishable new science vs. New and robust

Challenges in P-P Partnerships

Public vs. Private

Urge to publish vs. Generate IP
Highly specific interest vs. Broadly applicable product
Publishable new science vs. New and robust



Excellent relevant science

Conclusions



Conclusions

- P-P partnerships important part of FlexGen's strategy
- P-P Partnerships do present challenges
- They require close collaboration and well defined research agreements
- We would be happy to discuss opportunities with potential partners in the audience.

